Ab cellera stock bot
On July 10, 2026, AbCellera Biologics Inc. (ABCL) shares experienced a 6.72% decline, closing at $6.80, as investors engaged in profit--taking following a significant year--to--date rally. Despite this intraday stumble, the company maintains a "Very Strong" momentum score of 94, according to AAII, reflecting its 76% gain in 2026. Market analysts attribute the recent volatility to the stock reaching a 52--week high in late June, driven by positive interim Phase 1 data for its lead program, ABCL635, and a first--quarter revenue beat.